Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, diabetes type 2, diabetic nephropathy, dyslipidemia and obesity.
The University of Hong Kong has patented RNA polymerase β subunit/RNA polymerase sigma factor RpoD (bacterial) interaction inhibitors reported to be useful for the treatment of gram-positive bacterial infections.
Kymera Therapeutics Inc. has described proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a signal transducer and activator of transcription 6 (STAT6)-targeting moiety.
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies activating the immune system to kill tumor cells, representing a major advancement in cancer treatment. However, by activating T-cell immunity, ICI treatment can lead to immune-related adverse events affecting the several organs, including the heart.
Previous studies have shown that protein expression of DOCK7 is increased in skeletal muscle biopsies from patients with Duchenne muscular dystrophy (DMD), leading researchers from the University of Alabama at Birmingham and affiliated organizations to assess the functional impact of DOCK7 on normal muscle and embryonic development of zebrafish.
Alzamend Neuro Inc. recently presented pharmacokinetic data for the lithium-based sparing therapy AL-001, a lithium salicylate/L-proline co-crystal, in 5XFAD mice, a murine model of Alzheimer’s disease (AD).
Scientists at Zhengzhou University and affiliated organizations synthesized and optimized a series of thienopyridine indole derivatives leading to the identification of compound [I] as the lead tubulin polymerization inhibitor with broad-spectrum antiproliferative activity.
Researchers from the University of Queensland recently provided details on the discovery and preclinical characterization of a new hematopoietic prostaglandin D2 synthase (HPGDS) inhibitor, CLS-189, being developed for the treatment of Duchenne muscular dystrophy (DMD).
Actinium Pharmaceuticals Inc. has unveiled ATNM-400, a novel non-PSMA-targeting, first-in-class radiotherapy for prostate cancer utilizing the Actinium-225 (Ac-225) radioisotope.
At this week’s American Chemical Society Spring meeting, Galderma SA reported the discovery of novel, oral and selective macrocyclic inhibitors of protein kinase C θ (PKCθ) for the potential treatment of atopic dermatitis (AD) and psoriasis.
RSS
